Tarsus Pharmaceuticals develops and sells eye care treatments, including XDEMVY for an eyelid condition caused by mites. TARS reports earnings on Tue, Nov 3, 2026. Analyst consensus is Strong Buy, based on the latest ratings from 4 firms (4 buy, 0 hold, 0 sell). In the past 30 days there were 1 dark pool print.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Sep 24 | Goldman Sachs | Reinstated | Buy | |
| Sep 16 | Barclays | Reinstated | Buy | |
| Sep 8 | Jefferies | Maintained | Buy | |
| Aug 12 | Oppenheimer | Maintained | Buy | |
| Jul 31 | Mizuho | Maintained | Buy |
Whale Options Flow
90DNo whale options trades in TARS in the last 90 days.
Dark Pool
30DAI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether TARS is in one of them and how their past TARS trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered TARS in an article yet. Here's the latest on the wider market.
About Tarsus Pharmaceuticals
Tarsus Pharmaceuticals is a biopharmaceutical company based in Irvine, California, focused on developing and selling treatments for eye care. Its main product, XDEMVY, is an eye solution approved in the United States for Demodex blepharitis, an inflammation of the eyelids caused by mites. The company markets this product to eye care professionals and is developing other treatments, including candidates for ocular rosacea and for preventing Lyme disease.
- Headquarters
- Irvine, CA